Weight-loss drugs for heart failure with obesity
Part of Heart & circulation, Hormones & metabolism, Lungs & breathing clinical trials.
This study is a registry (a database) that will gather information about people with obesity and a type of heart failure where the heart pumps normally but doesn't fill properly. The goal is to see how well a new class of weight-loss and diabetes drugs (called GLP-1/GIP agonists) might help these patients feel better and exercise more easily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your body mass index (BMI) is 30 or higher, which is in the obesity range.
- You have heart failure with a normal pumping function (called HFpEF) and have symptoms like shortness of breath or fatigue.
- You can do a bicycle exercise test while lying back, and you agree to join the registry and have your data used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether incretin-based diabetes medications (like GLP-1 drugs) can help people with a specific type of heart failure called HFpEF that is linked to obesity. The goal is to see if these drugs improve heart function and symptoms.
This study tests whether weight loss from a medication can improve how you feel, move, and how well your heart works. It's for people who have both obesity and heart failure with reduced pumping strength.
This study looks at how higher body weight and weight loss affect people who have heart failure with preserved pumping strength. It uses heart scans to measure how the heart and body change, which may help guide future treatment plans.
This study tests whether a new medication called NNC0487-0111 can help people with heart failure who also have obesity. Researchers will compare it to a placebo (inactive pill) to see if it improves heart function and overall health.
This study looks at how obesity and weight loss affect people living with heart failure where the heart pumping strength is reduced. It uses heart imaging (MRI) to measure the heart and may help clarify what weight changes do for symptoms and heart function.
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.